Cell:挑战常规!特异性tRNA促进肿瘤转移

2016-06-05 佚名 生物谷

在任何给定的时刻,人基因组拼出上千个遗传密码单词(即密码子),这些单词告诉我们的细胞制造哪些蛋白。每个单词是由tRNA分子读取的。美国洛克菲勒大学伊丽莎白与文森特-迈耶系统癌症生物学实验室(Elizabeth and Vincent Meyer Laboratory of Systems Cancer Biology)主任Sohail Tavazoie解释道,“我们长期认为这些tRNA分子的作

在任何给定的时刻,人基因组拼出上千个遗传密码单词(即密码子),这些单词告诉我们的细胞制造哪些蛋白。每个单词是由tRNA分子读取的。

美国洛克菲勒大学伊丽莎白与文森特-迈耶系统癌症生物学实验室(Elizabeth and Vincent Meyer Laboratory of Systems Cancer Biology)主任Sohail Tavazoie解释道,“我们长期认为这些tRNA分子的作用差不多就是参与蛋白翻译过程的中间者。”但是在他的实验室开展的一项新研究提示着tRNA动态变化可能在调节细胞内的蛋白类型中发挥着重要作用。

在这项新的研究中,Tavazoie和他的同事们描述了tRNA数量波动如何能够不仅对单个细胞的命运产生显著影响,而且也对转移性乳腺癌等疾病产生显著影响。相关研究结果发表在2016年6月2日那期Cell期刊上,论文标题为“Modulated Expression of Specific tRNAs Drives Gene Expression and Cancer Progression”。

拼写很重要

英语中的一些单词能够拥有不止一种拼写方式---比如“color”和“colour”,表达都是“颜色”的意思。同样的情形也适用于我们的遗传密码。

当细胞激活一个基因表达蛋白时,它的基因组拼出被称作密码子的三字母单词。每个密码子特异性地对应着蛋白中的一个氨基酸。但是在一些情形下,两个或多个密码子对应着同一个氨基酸。这些密码子被tRNA读取,每个tRNA对应着拼出的每个三字母单词。

所有生物使用相同的遗传密码,但是密码子使用和tRNA可获得性在不同生物和不同组织之间存在差异---正如“colour”主要在英国使用,而“color”在美国更加常见。

微小变化产生重大影响

几十年来,科学家们认为这些tRNA对细胞功能没有什么影响。但是这些tRNA分子一直很难研究,因此Tavazoie团队想要知道tRNA数量变化是否能够影响细胞功能。

Tavazoie说,“传统上,使用标准方法定量确定细胞中的tRNA含量是比较困难的。”

论文第一作者Hani Goodarzi和Hoang Nguyen设计和采用一种涉及最新基因组测序技术的新方法来测量不同类型细胞中的tRNA数量。

研究人员选择对来自健康人的乳腺组织和来自乳腺癌---包括还没有从乳腺扩散到其他身体位点的原发性乳腺瘤和高度侵袭性的转移性乳腺瘤---患者的肿瘤样品进行比较。

他们发现两种特异性的tRNA在转移性乳腺癌细胞和转移性乳腺瘤中的水平显著高于未发生肿瘤转移的原发性乳腺瘤和健康样品。Tavazoie解释道,“有4种不同的方法编码蛋白中的精氨酸(编者注:有4个不同密码子编码精氨酸,因此也有4个不同的tRNA分子识别这些密码子)。但是在这些tRNA分子中,只有识别密码子CGG的tRNA与增加的肿瘤转移相关联。”

识别密码子GAA(编码谷氨酸)的tRNA水平也在转移性乳腺瘤样品中上升了。

研究人员猜测这两种tRNA水平增加可能事实上促进肿瘤转移。通过研究未发生肿瘤转移的原发性乳腺瘤模式小鼠,他们增加这些tRNA的产生,从而使得这些原发性乳腺瘤细胞更加具有浸润性和转移性。

研究人员也开展相反的实验,并且获得预期的结果:在转移性乳腺瘤细胞中降低这些tRNA的水平就会降低这些小鼠的肿瘤转移发生率。

促进肿瘤转移

这两种tRNA如何促进肿瘤转移?研究人员在这两种tRNA水平增加的原发性乳腺瘤细胞中观察蛋白表达变化。

Tavazoie说,“我们发现几十个基因表达水平全部增加,因此我们分析了它们的序列,结果发现它们中的绝大多数具有数量显著增加的这两个密码子。”

根据研究人员的说法,两种基因EXOSC2和GRIPAP1在其中脱颖而出。这种特异性谷氨酸tRNA水平增加强效地和直接地诱导这两种基因表达。

Tavazoie解释道,“当我们将密码子GAA突变为密码子GAG---一种‘沉默的’突变,这是因为它们编码蛋白中的谷氨酸---时,我们发现增加这种突变后的tRNA数量不再增加蛋白表达水平。”研究人员发现这些蛋白促进乳腺瘤转移。

根据研究人员的说法,这项研究对tRNA如何发挥功能的现有猜测提出挑战,并且提示着tRNA能够调节基因表达。Tavazoie指出“令人显著的是,在单个细胞中,基因序列的同义突变能够显著地影响特异性蛋白水平、它们的转录本水平和细胞的行为方式。”

原始出处

Hani Goodarzi, Hoang C.B. Nguyen3, Steven Zhang, Brian D. Dill, Henrik Molina, Sohail F. Tavazoie.Modulated Expression of Specific tRNAs Drives Gene Expression and Cancer Progression.Cell.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1899085, encodeId=ba6218990856a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Jul 20 01:16:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959665, encodeId=a9c9195966552, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Dec 20 23:16:00 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869408, encodeId=6a261869408f2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Feb 03 18:16:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291621, encodeId=93331291621dc, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486555, encodeId=fc8b1486555ac, content=<a href='/topic/show?id=cd401e84239' target=_blank style='color:#2F92EE;'>#tRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17842, encryptionId=cd401e84239, topicName=tRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89bf8152050, createdName=liao1622, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88765, encodeId=20e088e6587, content=这个不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:03:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88766, encodeId=5b8088e6609, content=已经学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:03:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88764, encodeId=702188e64cf, content=是这个样子, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:02:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88603, encodeId=9a628860391, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1899085, encodeId=ba6218990856a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Jul 20 01:16:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959665, encodeId=a9c9195966552, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Dec 20 23:16:00 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869408, encodeId=6a261869408f2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Feb 03 18:16:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291621, encodeId=93331291621dc, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486555, encodeId=fc8b1486555ac, content=<a href='/topic/show?id=cd401e84239' target=_blank style='color:#2F92EE;'>#tRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17842, encryptionId=cd401e84239, topicName=tRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89bf8152050, createdName=liao1622, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88765, encodeId=20e088e6587, content=这个不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:03:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88766, encodeId=5b8088e6609, content=已经学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:03:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88764, encodeId=702188e64cf, content=是这个样子, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:02:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88603, encodeId=9a628860391, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-12-20 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1899085, encodeId=ba6218990856a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Jul 20 01:16:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959665, encodeId=a9c9195966552, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Dec 20 23:16:00 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869408, encodeId=6a261869408f2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Feb 03 18:16:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291621, encodeId=93331291621dc, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486555, encodeId=fc8b1486555ac, content=<a href='/topic/show?id=cd401e84239' target=_blank style='color:#2F92EE;'>#tRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17842, encryptionId=cd401e84239, topicName=tRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89bf8152050, createdName=liao1622, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88765, encodeId=20e088e6587, content=这个不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:03:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88766, encodeId=5b8088e6609, content=已经学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:03:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88764, encodeId=702188e64cf, content=是这个样子, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:02:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88603, encodeId=9a628860391, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1899085, encodeId=ba6218990856a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Jul 20 01:16:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959665, encodeId=a9c9195966552, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Dec 20 23:16:00 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869408, encodeId=6a261869408f2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Feb 03 18:16:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291621, encodeId=93331291621dc, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486555, encodeId=fc8b1486555ac, content=<a href='/topic/show?id=cd401e84239' target=_blank style='color:#2F92EE;'>#tRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17842, encryptionId=cd401e84239, topicName=tRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89bf8152050, createdName=liao1622, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88765, encodeId=20e088e6587, content=这个不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:03:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88766, encodeId=5b8088e6609, content=已经学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:03:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88764, encodeId=702188e64cf, content=是这个样子, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:02:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88603, encodeId=9a628860391, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1899085, encodeId=ba6218990856a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Jul 20 01:16:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959665, encodeId=a9c9195966552, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Dec 20 23:16:00 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869408, encodeId=6a261869408f2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Feb 03 18:16:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291621, encodeId=93331291621dc, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486555, encodeId=fc8b1486555ac, content=<a href='/topic/show?id=cd401e84239' target=_blank style='color:#2F92EE;'>#tRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17842, encryptionId=cd401e84239, topicName=tRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89bf8152050, createdName=liao1622, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88765, encodeId=20e088e6587, content=这个不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:03:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88766, encodeId=5b8088e6609, content=已经学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:03:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88764, encodeId=702188e64cf, content=是这个样子, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:02:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88603, encodeId=9a628860391, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-07 liao1622
  6. [GetPortalCommentsPageByObjectIdResponse(id=1899085, encodeId=ba6218990856a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Jul 20 01:16:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959665, encodeId=a9c9195966552, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Dec 20 23:16:00 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869408, encodeId=6a261869408f2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Feb 03 18:16:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291621, encodeId=93331291621dc, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486555, encodeId=fc8b1486555ac, content=<a href='/topic/show?id=cd401e84239' target=_blank style='color:#2F92EE;'>#tRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17842, encryptionId=cd401e84239, topicName=tRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89bf8152050, createdName=liao1622, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88765, encodeId=20e088e6587, content=这个不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:03:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88766, encodeId=5b8088e6609, content=已经学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:03:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88764, encodeId=702188e64cf, content=是这个样子, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:02:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88603, encodeId=9a628860391, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-06 milkshark

    这个不错

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1899085, encodeId=ba6218990856a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Jul 20 01:16:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959665, encodeId=a9c9195966552, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Dec 20 23:16:00 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869408, encodeId=6a261869408f2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Feb 03 18:16:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291621, encodeId=93331291621dc, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486555, encodeId=fc8b1486555ac, content=<a href='/topic/show?id=cd401e84239' target=_blank style='color:#2F92EE;'>#tRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17842, encryptionId=cd401e84239, topicName=tRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89bf8152050, createdName=liao1622, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88765, encodeId=20e088e6587, content=这个不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:03:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88766, encodeId=5b8088e6609, content=已经学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:03:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88764, encodeId=702188e64cf, content=是这个样子, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:02:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88603, encodeId=9a628860391, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-06 milkshark

    已经学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1899085, encodeId=ba6218990856a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Jul 20 01:16:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959665, encodeId=a9c9195966552, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Dec 20 23:16:00 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869408, encodeId=6a261869408f2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Feb 03 18:16:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291621, encodeId=93331291621dc, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486555, encodeId=fc8b1486555ac, content=<a href='/topic/show?id=cd401e84239' target=_blank style='color:#2F92EE;'>#tRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17842, encryptionId=cd401e84239, topicName=tRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89bf8152050, createdName=liao1622, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88765, encodeId=20e088e6587, content=这个不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:03:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88766, encodeId=5b8088e6609, content=已经学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:03:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88764, encodeId=702188e64cf, content=是这个样子, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:02:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88603, encodeId=9a628860391, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-06 milkshark

    是这个样子

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1899085, encodeId=ba6218990856a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Jul 20 01:16:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959665, encodeId=a9c9195966552, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Dec 20 23:16:00 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869408, encodeId=6a261869408f2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Feb 03 18:16:00 CST 2017, time=2017-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291621, encodeId=93331291621dc, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486555, encodeId=fc8b1486555ac, content=<a href='/topic/show?id=cd401e84239' target=_blank style='color:#2F92EE;'>#tRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17842, encryptionId=cd401e84239, topicName=tRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89bf8152050, createdName=liao1622, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88765, encodeId=20e088e6587, content=这个不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:03:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88766, encodeId=5b8088e6609, content=已经学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:03:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88764, encodeId=702188e64cf, content=是这个样子, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:02:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88603, encodeId=9a628860391, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-05 沉心多思

    不错的文章,多学习

    0

相关资讯

CA Cancer J Clin:美国肿瘤幸存者人数逐年增加

近年来男性和女性的癌症发病率稳步下降,癌症幸存者的数量逐年增加。主要原因包括早期发现和治疗方式有效,此外还包括生活质量的提高使得人们寿命更长和人口基数增加。 研究人员指出,尽管人们对生命的认识程度得以提高,但是民众仍然面临许多严峻的挑战。该研究旨在分析当前癌症幸存者的数量和预测水平,研究结果发表在CA: A Cancer Journal for Clinicians。2016年常见癌症男性幸存者人

生物谷专访中国医学科学院肿瘤医院林东昕院士

编者按:近年来在精准医疗领域的研究和投资热度不减。尤其是针对癌症的早期诊断技术的开发如基因筛查等开始受到广泛的关注,吸引了越来越多的研究者投身其中。对于各类癌症发生的分子机制以及易感基因的研究则是这项技术的关键环节。中国医学科学院肿瘤医院病因及癌变研究室主任林东昕院士是肿瘤病因学领域的资深学者。林院士多年来致力于探索常见肿瘤发生发展及其遗传易感性的分子机制,较系统地研究了致癌物代谢、DNA修复

AACE 2016:使用PET/CT诊断高危肾上腺恶性肿瘤时应谨慎

近期一项研究结果表明,18F-氟脱氧葡萄糖(18FDG)PET / CT成像对肾上腺恶性肿瘤高危患者判断的敏感性和特异性较低,还需要联合临床判断。 梅奥诊所内分泌研究员Danae Delivanis博士和同事对352名(男性占62.5%,平均年龄68岁(18-91岁))患者进行了回顾性研究,探究18FDG-PET/CT成像技术对肾上腺恶性肿瘤高危人群的有效性。所有患者在1994-2014年间

生命不息、放疗不止?

导  语: 临床上有时候碰到的疾病,不是光靠NCCN指南就能横行天下,面对棘手的问题,治疗决策和道德情感往往在内心产生博弈。特别是作为一个肿瘤医生,面对一些肿瘤有手段可行,但给患者带来的结果却不见得可观,我们该做出怎样的选择? 最近有一例患者就引起了我的思考,她虽然不是我管的患者,但由于每次大查房的病例讨论,已让我对她的病情耳熟能详。 第一个部位放疗:胸壁及

Cell Reports: 肿瘤相关巨噬细胞的靶向抗体可以抑制肿瘤的发展和转移

肿瘤是由多种细胞类型组成的,除了肿瘤细胞自身,还包括其他的基质细胞,其中,先天性免疫细胞就是一种,如巨噬细胞。肿瘤相关巨噬细胞是位于肿瘤微环境中的一类异质性的单核细胞群。这些细胞发挥免疫抑制的作用,从而帮助肿瘤细胞生长和转移。该团队在研究中发现模式识别性清道夫受体MARCO(macrophagereceptorwithcollagenousstructure,具有胶原结构的巨噬细胞受体)是乳腺

Oncogene:烟草化合物诱导氧化应激促进肿瘤发展

上海交通大学基础医学院生化与分子细胞生物学系易静研究组在一项研究中,揭示了烟草化合物诱导氧化应激促进肿瘤发生和发展的原因。相关成果日前发表于《癌基因》杂志。头颈部癌是一类原发于头颈部的恶性肿瘤,在发生前往往存在长期的局部慢性炎症。头颈部癌与吸烟有明显关联。研究认为,吸烟诱发癌变和促进癌症发展的原因在于烟草成分损伤DNA并带来基因突变。此次研究人员发现,在有烟草化合物NNK存在时,细胞发生氧化应激,